ORKA
Oruka Therapeutics, Inc.
$34.41
%
Analyst Rating:Buy

Stock Details

CEO

Lawrence Otto Klein

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

28

Address

221 Crescent Street Building 23, Suite 105, Menlo Park, MA

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Oruka Therapeutics, Inc.  $34.41

EPS

Revenue

Congress Tracker 

Insider Trading of Key Employees

Financial News: ORKA